Manus Bio is awarded a Phase I STTR Grant from the National Science Foundation for the development of a novel pathway for terpenoid biosynthesis

CAMBRIDGE, Mass., June 15, 2013 - Manus Bio, a leader in metabolic engineering and synthetic biology, announced today that it has been awarded a prestigious National Science Foundation grant under the Small Business Technology Transfer (STTR) program. This Phase I award ($225,000) supports the design and engineering of a de novo pathway for terpenoid production. The full abstract for the project entitled “Overcoming Metabolic Pathway Limitations through De Novo Pathway Design for Terpenoid Biosynthesis” can be found at

About Manus Bio

Manus Bio is a global leader in the use of advanced fermentation technology for manufacturing complex, bioactive natural products as flavors, fragrances, food ingredients, biopesticides, and pharmaceuticals. The core team and technology are from MIT, and the company is headquartered in Cambridge, MA, USA. For more information, visit